European Journal of Surgical Oncology
Volume 32, Issue 10 , Pages 1097-1100 , December 2006

High incidence of BRCA1–2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma

  • T. Biron-Shental

      Affiliations

    • Department of Obstetrics & Gynecology, Meir Medical Center, Kfar Saba, Israel, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • ,
  • L. Drucker

      Affiliations

    • Oncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • ,
  • M. Altaras

      Affiliations

    • Department of Obstetrics & Gynecology, Meir Medical Center, Kfar Saba, Israel, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • ,
  • J. Bernheim

      Affiliations

    • Department of Pathology, Meir Medical Center, Kfar Saba, Israel, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • ,
  • A. Fishman

      Affiliations

    • Department of Obstetrics & Gynecology, Meir Medical Center, Kfar Saba, Israel, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 9 7472561; fax: +972 9 7472646.

,Accepted 22 March 2006.

References 

  1. Hendrickson M, Martinez A, Ross J, Kempson R, Eifel P. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108
  2. Rosenberg P, Blom R, Hogberg T, Simonsen E. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol. 1993;51:311–315
  3. Gallion HH, Nagell JR, Powell DF, Donaldson ES, Higgins RV, Kryscio RJ, et al. Stage I serous papillary carcinoma of the endometrium. Cancer. 1989;63:2224–2228
  4. Ward BG, Wright RG, Free K. Papillary carcinomas of the endometrium. Gynecol Oncol. 1990;39:347–351
  5. Piura B, Meirovitz M, Shulman M, Yanai-Inbar I, Cohen Y. Uterine papillary serous carcinoma: study of 19 cases. Eur J Obstet Gynecol Reprod Biol. 1998;79:69–73
  6. Kato DT, Ferry JA, Goodman A, Sullinger J, Scully RE, Goff BA, et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 1995;59:384–389
  7. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Eng J Med. 1997;336:1401–1408
  8. Modan B, Gak E, Sade-Bruchim RB, Hirsh-Yechezkel G, Theodor L, Lubin F, et al. High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. JAMA. 1996;276:1823–1825
  9. Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel. Frequency and differential penetrance in ovarian cancer and in breast–ovarian cancer families. Am J Hum Genet. 1997;60:1059–1067
  10. Hornreich G, Beller U, Lavie O, Renbaum P, Cohen Y, Levy-Lahad E. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol. 1999;75:300–304
  11. Goshen R, Chu W, Elit L, Pal T, Hakimi J, Ackerman I, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast–ovarian cancer syndrome?. Gynecol Oncol. 2000;79:477–481
  12. Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy Lahad E, Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol. 2000;96:28–32
  13. Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol. 2004;92:521–524
  14. Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol. 2001;83:501–503
  15. Rohlfs EM, Learning WG, Friedman KJ, Couch FJ, Weber BL, Silverman LM. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem. 1997;43:24–29
  16. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997;60:505–514
  17. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–187
  18. Boyd J. Specific keynote: hereditary ovarian cancer: what we know?. Gynecol Oncol. 2003;88:8–10
  19. Levine DA, Lin O, Baraket RR, Robson ME, McDermott D, Cohen L, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 2001;80:395–398
  20. Goldman NA, Goldberg GL, Runowicz CD, Anderson PS, Fields AL. BRCA mutations in women with concurrent breast cancer and uterine papillary serous carcinoma. ASCO Proc. 2002;21:221a
  21. Caduff RF, Sovoboda-Newman SM, Bartons RE, Ferguson AW, Frank TS. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol. 1998;22:319–326
  22. Karlan BY. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol Oncol. 2004;92:519–520

PII: S0748-7983(06)00145-4

doi: 10.1016/j.ejso.2006.03.032

European Journal of Surgical Oncology
Volume 32, Issue 10 , Pages 1097-1100 , December 2006

Article Tools